Stephen Hill's Insider Trades & SAST Disclosures
Stephen Hill's most recent trade in Lyell Immunopharma Inc was a trade of 450,000 Option (right to buy) done . Disclosure was reported to the exchange on Feb. 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Stephen Hill.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lyell Immunopharma Inc | Stephen Hill | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 450,000 | 450,000 | - | - | Option (right to buy) | |
| Lyell Immunopharma Inc | Hill Stephen | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 112,500 | 172,899 | - | 0 | Common Stock | |
| Lyell Immunopharma Inc | Hill Stephen | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 56,250 | 56,250 | - | - | Option (right to buy) | |
| Avalonbay Communities Inc. | Stephen P. Hills | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 980 | 7,576 (0%) | 0% | 0 | Common Stock, par value $.01 per share | |
| Lyell Immunopharma Inc | Stephen Hill | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 400,000 | 400,000 | - | - | Stock Option (right to buy) | |
| Lyell Immunopharma Inc | Stephen Hill | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 40,000 | 48,928 | - | 0 | Common Stock | |
| Avalonbay Communities Inc. | Stephen P. Hills | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 990 | 6,380 (0%) | 0% | 0 | Common Stock, par value $.01 per share | |
| Lyell Immunopharma Inc | Stephen Hill | Chief Technical Ops. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 900,000 | 900,000 | - | - | Option (right to buy) | |
| Avalonbay Communities Inc. | Stephen P. Hills | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 852 | 5,217 (0%) | 0% | 0 | Common Stock, par value $.01 per share | |
| Lyell Immunopharma Inc | Stephen Hill | Chief Technical Ops. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2022 | 700,000 | 700,000 | - | - | Option (right to buy) | |
| Avalonbay Communities Inc. | Stephen P. Hills | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 833 | 4,264 (0%) | 0% | 0 | Common Stock, par value $.01 per share | |
| Lipocine Inc | Stephen A. Hill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2020 | 7,500 | 12,750 (0%) | 0% | 0 | Common Stock | |
| Lipocine Inc | Stephen A. Hill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2020 | 7,500 | 7,500 | - | - | Restricted Stock Unit | |
| Cellectar Biosciences Inc | Stephen A. Hill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2020 | 50,000 | 50,000 | - | - | Stock option (right to buy) | |
| Lipocine Inc | Stephen A. Hill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2020 | 22,000 | 22,000 | - | - | Stock Options (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges